

[Dr. Lee P. Schacter](#), PhD, MD initially trained as a bench scientist and maintains an active basic research program. After medical training in medical oncology, in which he is board certified, he was on the faculty of Case Western Reserve. He transitioned to the drug industry at Bristol-Myers (Squibb) where he helped evaluate more than 15 potential cancer drugs, designed and conducted clinical trials, and served on the licensing committee that evaluated several hundred opportunities. After 12 years, an NDA and a sNDA he returned to academia at Yale as Associate Director of the Cancer Center for Clinical Research. While there he chaired the Scientific Review Board, served on the Human Investigations Committee (IRB), was responsible for the operations of the data management office and continued to serve as a consultant for a number of biotech companies including Vion and CarboMed. He then took a position with Astra-Zeneca in order to work with targeted therapies which were then unproven. After Astra-Zeneca he was Senior VP for clinical development and CMO for Protarga, a startup biotech. When its lead compound failed, he was Global Head of Oncology for MDS Pharma Services leaving to work as an independent consultant/contractor for a variety of companies including Incyte, Sopherion, Sapphire, Boston Life Sciences, Hybridon and J&J. After buying an apartment in Manhattan he took a position with Pfizer as Senior Director of Medical Affairs where, amongst other functions he again served on the licensing committee. After Pfizer he was a Senior Director for Clinipace and then Novella Clinical where he continues to work as a contractor.

From 1986 to 1996 and again from 2000 to 2015 he saw patients weekly at the West Haven and Philadelphia VA medical centers without compensation.

Dr. Schacter has extensive experience in all phases of cancer drug development and trial conduct. He has worked with cytotoxics, targeted therapies, immune therapies, antibody drug conjugates and other treatment modalities. He is currently directing and funding a research program to discover the compound(s) that cause asymptomatic weight loss in some cancer patients.

When not engaged in medical research Dr. Schacter is an avid sailor and restores mid-century Lionel trains.